Bringing breakthroughs in efficacy, safety, cost and time to patients with cancer
Vicus Therapeutics is a private biopharmaceutical company dedicated to bringing breakthrough adjunct therapies to patients with cancer. Vicus focuses on identifying "first-in-class-to-a-cancer" repurposed generic drugs that have already gained FDA approval for non-cancer indications and have completed initial clinical testing for the treatment of cancer-related indications.
Vicus partners with pharmaceutical companies and then develops these potential breakthrough drugs as components of multi-drug treatment regimens that can enhance the effectiveness of the partners’ FDA-approved targeted oncology drug products. Because all the components of the multi-drug regimens are already FDA-approved drugs, patients can gain access to the new treatments much more rapidly than if the components were New Chemical Entities requiring extensive, costly and time consuming evaluations.
Vicus’ lead product, VT-122, is designed to enhance the effectiveness of targeted drug therapies for advanced cancer patients with systemic inflammation. Systemic inflammation in advanced cancer manifests as cachexia and is associated with poor tolerance, adherence and response to anti-therapy, poor quality-of-life and reduced life expectancy. In a Phase 2 study of advanced lung cancer patients, VT-122 demonstrated a statistically significant improvement in lean body mass, an endpoint reflective of systemic inflammation.